Evaluation of New Iron Chelators for Clinical Use

Acta Haematologica

Volumn 95, Issue 1, 1996, Pages 13-25

  Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Hydroxypyridinone; Iron chelators; Iron overload; Ribonucleotide reductase

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; CHELATING AGENT; DEFERIPRONE; RIBONUCLEOTIDE REDUCTASE;

AGRANULOCYTOSIS; APOPTOSIS; ARTICLE; BLOOD TRANSFUSION; CYTOSTASIS; DRUG METABOLISM; DRUG SAFETY; DRUG USE; HUMAN; IRON METABOLISM; IRON OVERLOAD; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THALASSEMIA MAJOR; TISSUE CULTURE;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HEMOSIDEROSIS; HUMANS; IRON; IRON CHELATING AGENTS; SPECIES SPECIFICITY;

EID: 0030051137     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203852     Document Type: Article

References (40)

1. Hoycs KP, Porter JB: Subcellular distribution of desfcrrioxamine and hydroxypyridin-4-onc chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993: 85:393-400.
2. Finch CA. Ragan HA. Dyer IA. Cook JD: Body iron loss in animals. Proc Soc Exp Biol Med 1978:159:335-338.
3. Porter JB. Abeysinghe RD. Hoyes KP. Barra C. Huchns ER. Brooks PN, Blackwell MP, Arane-ta M. Brittenham G, Singh S. Dobbin P. Hider RC: Contrasting interspecies efficacy and toxicology of 1.2-diethyl-3-hvdroxypyridin-4-one. CP94, relates to differing metabolism of the iron chelating site. Br J Haematol 1993:85: 159-168.
4. Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN. Huehns ER, Hider RC: Comparison of the subacute toxicity and efficacy of orally active 3-hydroxypvridin-4-one iron chelators. Blood 1991:78:2727-2734.
5. Singh S, Epemolu RO, Dobbin PS, Ellis BL, Tilbrook GS, Damani LA, Hider RC: Urinary metabolic profile in man and rat of 1.2-dime-thyl and 1,2-diethyl substituted 3-hydroxypy-ridin-4 ones. DrugMetab Dispos 1992:20:256— 261.
6. Porter JB, Morgan J. Hoyes KP, Burke LC. Huchns ER. Hider RC: Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chclators in mice. Blood 1990:76:2389-2396.
7. Hoyes KP, Abeysinghe RD. Jones HM. Hider RC, Porter JB: In vivo and in vitro effects of 3 hydroxypyridin-4-one chelators on murine haemopoiesis. Exp Haematol 1993:21:86-92.
8. Berdoukas V. Bentley P. Frost H. Schncbli HP: Toxicity of iron chelator LI. Lancet 1993:341: 1088.
9. Wong A, Berdoukas V, Robertson D, Taylor E, Alder V, Papadimitriou J, Maserei J, Konto-ghiorghes G, Baker E: Toxicity and cfficacy of I,2-dimethy!-3-hydroxypyridin-4-one (LI: CP20) in the guinea pig. Program and Abstracts 11th Int Confon Iron and Iron Proteins, Jerusalem. 1993.
10. Bergeron RJ. Strciff RR. Weigand J. Luchetta G. Crcan’ EA. Peter HH: A comparison of the iron clearing properties of l,2-dimethyl-3-hv-droxypyrid-4-one. 1,2-diethyl-3-hydroxypyrid-40-one and desferrioxamine. Blood 1992:79: 1882-1890.
11. Gralla EJ, Burgess DH: Iron retention and excretion in mice transfused with homologous and heterologous blood treated with chelators. Methods Find Exp Clin Pharmacol 1982;4: 151-159.
12. Graziano JH. Grady RW. Cerami A: The identification of 2.dihydroxybcnzoic acid as a potentially useful iron-chelating drug. J Pharmacol ExpTher 1974:196:478-485.
13. Hcrshko C, Grady RW, Cerami A: Mcchanism of iron chelation in the hypcrtransfuscd rat: Definition of two alternative pathways of iron mobilisation. J Lab Clin Med 1978:92:144— 151.
14. Carthew P. Dorman BM. Edwards RE. Francis JE. Smith AG: A unique rodent model for both cardiotoxic and heptatotoxic effects of prolonged iron overload. Lab Invest 1993:69:217-222.
15. Florence A, Ward RJ. Peters T.I, Crichton RR: Studies of iron mobilisation by chelators in the ferrocene loaded rat. Biochem Pharmacol 1992:44:1023-1027.
16. Neilsen P, Hcinelt S, Dullmann J: The regulation of iron absorption in the carbonyl iron and the TMH-ferrocene model for experimental iron overload in rats. Comp Biochem Physiol 1993:106:429-436.
17. Pitt CG, Gupta G, Estes WE, Rosenkranz H, Metterville JJ, Grumbliss AL, Palmer RA, Nordqucst KW, Sprinklehardy KA, Whit-combe DR, Byers BR, Areneaux JE, Gaines CG, Sciortino CV: Selection and evaluation of new chclating agents for the treatment of iron overload. J Pharmacol ExpTher 1979:208:12— 18.
18. Hershko C, Cook JD, Finch DA: Storage iron kinetics. Ill: Study of desfernoxamine action by selective radioiron labels of RE and paren-chvmal cells. J Lab Clin Med 1973:81:876-886.
19. Hershko C, Avramovici-Grisaru S. Link G, Gclfand L. Sarei S: Mcchanism of in vivo iron chelation by pyridoxal isonicotinovl hydrazonc and other imino derivatives of pyridoxal. J Lab Clin Med 1981:98:99-108.
20. Pippard MJ, Johnson DK, Finch CA: A rapid assay for evaluation of iron chclating agents in rats. Blood 1981:58:685-691.
21. Carthew P, Smith AC, Hider RC, Dorman B, Edwards RE, Francis JE: Increased accumulation of iron in cardiac myocytes due to the treatment of iron overload in gerbils with the hydroxypvridinonc iron chelator CP94. Bio-materials. in press.
22. Olivieri NF. Koren G. Herman C, Bcntur Y. Chung D. Klein J, St Louis P. Freedman MH. McClelland RA. Templeton DM: Comparison of oral iron chelator LI and desfernoxamine in iron loaded patients. Lancet 1990:336:1275— 1279.
23. Al Refaie FN. Wonkc B, Hoffbrand AV, Wickcns DG. Nortey P. Kontoghiorghes GJ: EITicacy and possible adverse effccts of the oral iron chclator l,2-dimethyl-3-hydroxypyridin-4-onc (LI) in thalassemia major. Blood 1992: 80:593-599.
24. Agarwal MB, Gupte SS. Viswanathan D. Ra-manathan J. Desai N, Puniyani RR, Chhablani AT: Long term assessment of efficacy and safety of LI, an oral iron chclator in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992:82:460-466.
25. Grady RW, Srinivasan JBD, Dunn JB. Hil-gartner MW: Toxicity associated with DMHP (LI) the new oral iron chclator (abstract). Pac-diatrRes 1990:27:142A.
26. Baker E. Wong A. Peter H. Jacobs A: Desferri-thiocin is an effective iron chclator in vivo and in vitro but ferrithiocin is toxic. Br J Haematol 1992:81:424-431.
27. Pippard MJ. Pattanapanyssat K. Tiperkae J. Hider RC: Metabolism of the iron chelates of desfcrrioxamine and hydroxypyridinones in the rat. Proc Eurlron Club. Budapest, 1989.
28. Hcrshko C. Link G. Pinson A. Peter HH. Dobbin P. Hider RC: Iron mobilisation from myocardial cells by 3-hydroxypvridin-4-one chelators: Studies in rat heart cell culture. Blood 1991;77:2049-2053.
29. Porter JB, Gyparaki M. Burke LC. Huchns ER, Sarpong P. Saez V. Hider RC: Iron mobilisation from hcpatocyte monolayer cultures by chelators: The importance of membrane permeability and the iron binding constant. Blood 1988:72:1479.
30. Dobbin PS. Hider RC. Hall AD, Taylor PD. Sarpond P. Porter JB. Xiao G, Ven dcr Helm D: Synthesis, physicochemical properties and biological evaluation on N substituted 2-alkyl-3-hydroxy-4(lh)-pyridinoncs. J Med Chcm 1993:36:2448-2458.
31. Hamilton KO, Stallibrass L, Hassan IF, Jin Y, Halleaux C, Mackav MW: The transport of two iron chelators, desfcrrioxamine and LI across Caco-2 monolayers. Br J Haematol 1994:86: 851-857.
32. Hoyes KP. Hider RC. Porter JB: Cell cycle synchronisation and growth inhibition by 3-hydroxypyridinonc iron chelators in leukaemia cell lines. Cancer Res 1992;52:4591-4599.
33. Porter JB, Lvnagh GR. Cooper C, Hider RC, Cammack R: Contrasting inhibition of intracellular ribonucleotide reductase with dcsfer-rioxamine and hydroxypyridinone iron chelators using electron spin resonance (ESR) detection (abstract). Br J Haematol 1993:84 (suppl l):64.
34. Porter JB. Lynagh GR. Hider RC: Thymocyte apoptosis: A rapid model for comparative screening of iron chelators: Implications for treatment of iron overload in thalassaemia. Coll Inserm 1994;234:371-372.
35. Cooper C, Lynagh G, Hider RC, Cammack R, Porter JB: Inhibition of intracellular ribonucleotide reductase with desfcrrioxamine and hydroxypyridinone iron chelators using electron spin resonance (ESR) detection. J Biol Chcm, submitted.
36. Nathan D: An orally active iron chelator. N Engl J Med 1995;332:953-954.
37. Kontoghiorghes GJ. Goddard GJ. Bartlett MD. Sheppard LN: Pharmacokinetic studies in humans with the oral iron chelator 1,2-di-mcthvl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990;48:255-261.
38. Lange R, Lameijer W, Roozcndaal KL, Kers-tcn MJ: Pharmaceutical analysis and pharma-eokinctics of the oral iron chelator 1.2-di-methyl-3-hydroxypyrid-4-one (DMHP). 4th Int Conf on Oral Chelation. Cyprus, 1993.
39. Kontoghiorghes GJ. Bartlett AN, Hoffbrand JG. Goddard JG, Sheppard L, Barr J. Nortey P: Long term trial with the oral iron chelator 1.2-dimethyl-3-hydroxypyridin-4-onc (LI). Br J Haematol 1990:76:295-300.
40. Porter JB. Weir TB. Marshall L. Abeysinghe RD, Round JM. Brcnton D, Huehns ER, Epi-molou O. Singh S, Dobbin P. Hider RC: Iron balance and dose escalation studies with the orally active hvdroxypyridin-4-ones iron chelator. CP94. in iron overloaded humans. Program and Abstracts 4th Int Conf on Hemochromatosis and Clinical Problems of I ron Metabolism. Jerusalem. 1993.